A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs Quetmolimab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors EA Pharma; Eisai Co Ltd
- 17 Jul 2018 Status changed from active, no longer recruiting to completed.
- 10 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2017 Planned number of patients changed from 24 to 21.